Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So, this news has depressed the SP. I need to consider that. The market see this as a setback.
Jimbooo, I think you need to watch some of the presentations that Avacta have given. They are shouting about Affimers everyweek!
Diagnostics opportunities are never ending due to the nature of the way an Affimer works.
Therapeutic opportunities are also going to potentially huge once the stage 1 clinical trials are progressed later this year and into 2021.
If we consider that an Affimer is a 'software' which can be modified for multiple applications and you have some idea of what they are able to achieve.
Just look at this presentation just for today's application announcement -https://youtu.be/xXTFovsvZnQ.
News in 8 weeks time on this will come back from Integumen - sharing revenue for the applications which will be a repeat business model. Sewage treatment, cruise ships etc. The technology will give notification within 4 seconds from the inline technology!
This company could have new applications and opportunities every week forever. Such is the range of opportunities available to them. They can maximise revenue and IP from this technology.
Cheers,
Rich
@ Jimboo. I would like to think that Cytiva’s experience with the FDA would make the approval process somewhat straightforward, providing the test works of course.
If the affirmers were that fantastic they'd be shouting about them from the rooftops, saying how they're far more accurate than envisaged, rather than merely being 'encouraged' (my wife would write school reports to say a kids progress was 'encouraging' to be diplomatic when they were far behind were they should be) in their words, of course that sort of talk will get you labelled as a deramper on here despite being invested. I still think a viable product is some weeks off, unless Avacta happy to release at 'good enough' rather than perfect, I have no doubt when released it could be hugely beneficial over the length of time RT PCR testing takes and be used in environments where PCR testing isn't appropriate, and I'll probably rebalance my portfolio towards Avacta more. How long things like approval will take is what could limit its marketability and revenue. Hope the FDA turn it around quicker than they did for NCYT, otherwise you're talking 2-3 months
"Might it just be that the Affimers work so brilliantly that everyone is queuing up for a share in using this revolutionary science?"
Well, not according to the SP which is lower on this news than it was on Friday which was down from 130p the previous week...…..
Might it just be that the Affimers work so brilliantly that everyone is queuing up for a share in using this revolutionary science?
Thanks for your input there jag but after your view that " you just need an a4 piece of paper which picks up covid slap it in the sewage works and if it turns a certain color BINGO!" I think i'll leave the science to AS and his team and probably overlook your very well informed view that "saliva tests don't pick up covid or nowhere near enough to warrant use."
Muppet
so I take it on your post Jag189 you dont hold any shares in this stock then ?
Bit salty aren’t we jag. Still long on GDR & ODX?
I agree currently covid is the priority so the market only cares about that at the moment so news needs to be right
SP will crash and overly optimistic investors like yourself will be caught holding the bag - my view is the saliva tests don't pick up covid or nowhere near enough to warrant use.
I just hope we don't become like those companies that keep churning out new experiments and ideas instead of finalising the main ones and money just gets spent crazily like that.
What we need is firm updates on it all and closure to testing so orders can come flying in, also the market is getting tight now as more players are coming onto the scene so AVCT needs to get it right to persuade people to buy theirs compared to others like NCYT etc.
Mortgagefree. I disagree
Lth ers Know the big value is in cancer treatments
The market is really only interested in the covid tests. As seen by the share price.
If only generating these products was as simple as you jag189.....
we going to make a billion pound company by testing water? you just need an a4 piece of paper which picks up covid slap it in the sewage works and if it turns a certain color BINGO!
where are the rapid saliva tests?
This rns shows the demand for a product such as affirmers, this demand will not go away, even when this current c19 dies down, testing waste water is here to stay.
This is a surprise RNS for sure, But what it does show is what potential Avacta has with its tools.
I would really like to know once corvid is out of the way, what other jobs can be done with these Affirmers and technology that Avacta has.
For me the cancer chemo targeting, is the one, that if works could be mind blowing.
its just down to time and patience.
I also have to say, with all the avenues and deals trying to be finalised, AS must be working at least 20hrs a day.